ARA-290

ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the helix-B region of erythropoietin (EPO). It is non-erythropoietic — it does not stimulate red-blood-cell production — and in preclinical research is studied for selective activity at the innate repair receptor, a heteromeric complex of the EPO receptor and the beta-common receptor that mediates tissue protection and inflammation resolution. This separates its studied tissue-protective signalling from EPO's haematopoietic effects. Supplied at ≥99% HPLC purity for in-vitro research use only.

Native erythropoietin drives red-blood-cell production via the classical EPO receptor homodimer. ARA-290 is derived from EPO's helix-B domain but is engineered to engage only the innate repair receptor (EPOR/beta-common heteromer) rather than the haematopoietic homodimer. In research this means it can be used to study EPO's tissue-protective signalling pathways without the erythropoietic (red-cell-stimulating) activity — a key reason it is of interest as a research tool. Not for human consumption — for research use only.

Reconstitution: Add 1–2mL of bacteriostatic water slowly down the inside wall of the vial with a 31G syringe and swirl gently until dissolved; do not shake. A 10mg vial reconstituted with 1mL BAC water yields a 10mg/mL solution. Storage: Lyophilised — store at −20°C for up to 24 months. Reconstituted — refrigerate at 2–8°C and use within 4 weeks, protected from light. BAC water is available at /products/bac-water-10ml. Not for human consumption — for research use only.

Legal status: ARA-290 is legal to purchase in Australia for legitimate laboratory research purposes. It is not for human consumption, therapeutic, cosmetic, or veterinary use and is not TGA-approved. Purchasers must be 18+ and confirm research-only intent. Quality: each batch is independently verified by third-party HPLC at ≥99% purity with a full COA including HPLC purity %, mass spectrometry identity confirmation, and sterility screening. Full COAs are available in our COA Library.

Peptide Warehouse Australia stocks ARA-290 10mg and ships nationwide via Australia Post with full tracking. Orders placed before 12PM AEST dispatch the same business day from our Melbourne warehouse; orders after 12PM AEST dispatch the next business day. Standard Post $8.99 (2–6 business days); Express Post $13.99 (1–3 business days); free shipping on all orders over $199 AUD. All orders ship in discreet plain packaging with no external branding. Not for human consumption — for research use only.

ARA-290 (Cibinetide) is studied for selective activity at the innate repair receptor — a heteromeric complex of the EPO receptor and the beta-common receptor — which mediates tissue-protection and inflammation-resolution signalling distinct from EPO's red-cell-stimulating receptor. Not for human consumption — for research use only.

ARA-290 has been examined in preclinical and early clinical research in the context of small-fibre neuropathy and neuropathic pain models, tied to innate-repair-receptor signalling. These are research findings only; the compound is supplied strictly for research. Not for human consumption — for research use only.

Because the innate repair receptor is involved in resolving inflammation, ARA-290 has appeared in research examining inflammatory conditions including sarcoidosis models, focusing on tissue protection and immune modulation. This work is research-only and not TGA-approved. Not for human consumption — for research use only.

ARA-290 is derived from EPO's helix-B domain but engineered to engage only the innate repair receptor, not the classical EPO-receptor homodimer that drives red-cell production. This lets researchers study EPO's tissue-protective signalling without the erythropoietic (red-cell) effect. Not for human consumption — for research use only.